Bristol-Myers Squibb Company (BMY) stock declined in its latest intraday trading after successfully correcting its oversold levels on the relative strength indicators. However, continued negative pressure from trading below the previous 50-day SMA reinforces the stability and strength of the main short-term bearish trend, especially with trading along a descending line that supports this direction.

Therefore, we expect the stock to decline in its upcoming trading sessions as long as the resistance level of $46.17 holds, targeting the key support level of $42.95.

Todays stock forecast: Bearish.